PROSPECTIVE STUDY TO COMPARE INSULIN AND INSULIN ANALOGS IN TYPE II DIABETIC PATIENTS by Ks, Gireesha & M, Sumithra
Vol 10, Issue 7, 2017
Online - 2455-3891 
Print - 0974-2441
A PROSPECTIVE STUDY TO COMPARE INSULIN AND INSULIN ANALOGS IN TYPE II DIABETIC 
PATIENTS
GIREESHA KS1, SUMITHRA M2
1Department of Pharmacy Practice, Vels School of Pharmaceutical Sciences, Vels University, Chennai - 600 117, Tamil Nadu, India. 
2Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Vels University, Chennai, Tamil Nadu, India. 
Email: gireeshaks123@gmail.com
Received: 21 March 2017, Revised and Accepted: 19 April 2017
ABSTRACT
Objective: To compare the safety and quality of life of insulin and insulin analogues in Type II Diabetic patients.
Methods: 100 patients who are diagnosed with  type – II diabetes milletus are taken.In these 50 patients are of insulin analogues and 50 patients are 
of conventional insulin The safety was based on number of hypoglycemic events.Data was collected by using the EQ-5D questionnaire and EQ Visual 
Analogue scale (EQ-VAS) to assess the quality of life from the patient.
Result:The percentage of the patients who had hypoglycemic events in conventional insulin group is 54% (n=27) and insulin analogues group is 20% 
(n=10). Mean score points of QOL obtained by conventional insulin patients is 75.9 and by insulin analogues patients is  93.75
Conclusion: Insulin analogues group has low risk of hypoglycaemia when compared with the conventional insulin.The patient group who are in No 
problem category are found to have better QOL. The safety and QOL statistical differences constitute less likely among insulin and insulin analogues. 
The use of insulin analogues will continue to advance our efforts at improving diabetes care and treated related adverse outcomes can be reduced.
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INTRODUCTION
Diabetes mellitus is a metabolic disorder which is expected to persist 
as a most important health problem owing to its severe complications. 
Insulin is indicated for type 1 diabetes patients and for patients with 
type 2 diabetes if glycemic control cannot be achieved satisfactorily in 
the course of oral hypoglycemic therapy [1]. Insulin is a poly peptide 
hormone produced by the beta cells of the pancreatic islets. It regulate 
the metabolism of carbohydrate,  fats and protein by promoting the 
absorption of, especially glucose from the blood into fat, liver and 
skeletal muscle cells [2]. Insulin is differentiated into conventional 
insulin agents and insulin analogues. Conventional insulin agents are 
therapeutic regimen for treatment of diabetes mellitus which contracts 
with the newer intensive insulinotherapy. 
Human insulin and Intermediate acting neutral protamine hagedron 
insulin (NPH) are the types of conventional insulin agents. There 
is a variation in the insulin absorption with the basal formulations 
such as NPH due to their low and relatively constant levels between 
meals [3]. Insulin analogues is an altered form of human insulin. 
Rapid- acting insulin such as insulin lispro (Eli Lilly), insulin as part 
(Novo Nordisk), are most commonly used for controlling post prandial 
hyperglycemia.Long acting insulin analogues have more physiologic 
substitution than NPH glycemic control [4]. Analogues have low risk 
of hypoglycemia with long duration of action and have a greater 
consistency  than NPH [5]. Insulin analogues have more benefit in 
administration compared with human insulinsx [6]. Hypoglycemia is 
the most common side effect that may occur during insulin therapy. 
Symptoms of hypoglycemia includes: confusion, nausea, hunger, 
tiredness, perspiration, headache, heart palpitations, and numbness, 
around the mouth, tingling in the fingers, tremors, muscle weakness, 
blurred vision., lipodystrophy. Therapy with the insulin analogues 
provides better glycemic control and have low risk of hypoglycaemia. 
Lispro, shows better quality of life in most of the patients [8] switching 
from the human insulin to insulin analogues there was a significant 
decrease in hypoglycaemic episodes accompanied by a significant 
increase in treatment satisfaction [10] health related quality of life 




To compare the safety and QOL of insulin and insulin analogs in Type II 
diabetic patients.
Study design
A prospective observational study was conducted over a period of 
6 months. The data were collected from the patient’s case sheet, drug 
chart, and also through direct patient interview.
Study procedure
Patient inclusion criteria




•	 Patients	with	other	 comorbid	 conditions	 such	as	hypertension,	





with cognitive impairment and visual or hearing loss.
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•	 Each	 characteristic	has	mainly	 three	 levels	which	describe	 “no	
problem,”	“some	problem,”	and	“severe	problem,”	and	then	patients	
were asked to designate about his/her health state by ticking 




is used to say how good or bad of patient health state.
•	 The	patients	were	 asked	 to	draw	a	 line	 from	 the	box	below	 to	
whichever	point	on	the	scale	specifies	their	current	health	state.
•	 The	EQ-5D	questionnaire	and	EQ	visual	analog	scale	(EQ-VAS)	scores	
are anchored on 100=best imaginable health and 0=worst imaginable 
health of the patient.
Data Analysis
The data were examined using GraphPad Prism software, Fisher’s exact 
test, Microsoft XL, and T-test are used to determine the safety, and QOL 
between conventional insulin and insulin analog patients. The p<0.05 is 
considered statistically significant.
RESULT
Among 100 study patients, 50 patients were on conventional insulin 
and 50 patients were on insulin analogs. The percentage of the patients 
who had hypoglycemic events in conventional insulin group is 54% 
(n=27) and insulin analogs group is 20% (n=10). The percentage 
of the patients who never had hypoglycemic events in conventional 
insulin group is 46% (n=23) and in insulin analog group is 80% (n=40) 
individually. The possibility of hypoglycemia has been calculated using 
Fisher’s exact test (Table 1 and Fig. 1a, b).
Characteristics of the subjects based on EQ-5D questionnaire consist of 
mainly five dimensions such as mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. The grade given was described 
“no	problem,	and	“problem.”	Data	are	analyzed	using	GraphPad Prism 
software, Fisher’s exact test, T-test, for differentiation (Table 2 and 
Fig. 2a, b).
Comorbidity of the conventional insulin in the study population (n=50) 
included 15 patients (30%) with hypertension, 7 patients (14%) with 
cardiovascular disease, 3 patients (6%) with renal disease, 2 patients 
(4%) with anemia, 5 patients (10%) with thyroid disorder, 4 patients 
(8%) with gastrointestinal disease, 2 patients (4%) with diabetic 
nephropathy, 2 patients (4%) with joint disorders, 5 patients (10%) 
with respiratory disorders, and 5 patients (10%) with no comorbidity. 
Comorbidity is estimated using the percentage of comorbidity patients 
in conventional insulin (Table 3 and Fig. 3).
Comorbidity of the insulin analogs in the study population (n=50) 
included 10 patients (20%) with hypertension, 7 patients (14%) 
with cardiovascular disease, 2 patients (4%) with renal disease, 
1 patients (2%) with anemia, 10 patients (20%) with thyroid disorder, 
5 patients (10%) with gastrointestinal disease, 2 patients (4%) with 
joint disorders, 3 patients (6%) with respiratory disorders, and 
10 patients (20%) with no comorbidity. Comorbidity is estimated 
using the percentage of comorbidity patients in insulin analogs 
(Table 4 and Fig. 4).
The QOL of insulin and insulin analogs was evaluated based on the EQ-
5D VAS was given from the range of 0-100, in which 0=worst imaginable 
health status of the patient and 100=best imaginable health status 
of the patient and the mean score points obtained by conventional 
insulin patients is 75.9 and by insulin analogs patients is 93.75 
(Table 5 and Fig. 5).
DISCUSSION
A study conducted by Singh et al. [4] reported that therapy with the 
insulin analogs offers few clinical advantages over conventional insulins 
in the management of most patients with Type II diabetes. Although 
the evidence supporting the benefit of insulin analogs in terms of 
hypoglycemia is weak, these agents may be an option for patients with 
problematic	hypoglycemia	despite	optimization	of	conventional	insulin	
therapy.
Our results indicate that difference between the conventional insulin 
and insulin analogs is minimum in treatment of Type II DM.
A study conducted by Zinman [6] suggests that long-acting 
insulin analogs provide relatively peakless and more physiologic 
insulin replacement therapy than neutral protamine Hagedorn 
insulin. New basal insulin analogs have been developed with 
superior pharmacokinetic and pharmacodynamics properties; 
insulin degludec and a PEGylated insulin lispro. These agents 
are generally well tolerated and have been evaluated in Type II 
diabetes. In general rates of hypoglycemia in these trials were low, 
glucose control was comparable to currently available basal insulin 
analogs, and rates of nocturnal hypoglycemia were significantly 
and substantially lower.
Insulin analogs have statistically significant advantages for hypoglycemic 
events in Type II diabetic patients for nocturnal hypoglycemia; the 
results were not constant across NPH insulins.
Fig. 1: (a) Safety level of hypoglycemic events in insulin patients. 
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A study conducted by Shah et al. [7] estimated that by comparing with 
the EQ-VAS scores, beginning or changing insulin associated with a 
significant increase in health-related QOL (HRQOL).
HRQOL reported that increased statistically significant in people 
administering any insulin analog regimen and across all regions although 
there were some marked regional differences in reported HRQOL at 
baseline. This study suggests that analogs had its own capability in 
increasing the QOL. In similarity to this literature, our study suggests that 
there is no significant difference in QOL between conventional insulin and 
insulin analogs. The overall percentage of QOL found on 5 dimensions was 
more for analog group (75.9%) than the conventional group (93.75%).
Table 1: Impact of therapy between insulin and insulin analogs on safety level
Safety (hypoglycemic 
events)











Yes 27 (54) 10 (20)
No 23 (46) 40 (80 4.69 1.99-11.9 1.99 1.37-2.95 0.0008
Table 2: Characteristics of the subjects based on EQ-5D questionnaire















1. Mobility 13 37 7 43 0.46 0.18-1.28 0.71 0.49-1.12 0.21
2. Selfcare 15 35 10 40 0.58 0.22-1.43 0.77 0.53-1.21 0.35
3. Usual activity 27 23 17 33 0.43 0.19-1 0.66 0.44-0.98 0.0693
4. Pain 15 35 12 38 0.73 0.31-1.85 0.86 0.58-1.35 0.65
5. Anxiety 25 25 10 40 0.25 0.09-0.59 0.53 0.36-0.78 0.0031
5D: Five-dimensional
Fig. 2: (a) Characteristics of insulin patients based on EQ-five-
dimensional (5D) questionnaire. (b) Characteristics of insulin 
analogs patients based on EQ-5D questionnaire
b
a
Fig. 3: Distribution based on insulin comorbidity
Fig. 4: Distribution based on insulin analogs comorbidity
Fig. 5: EQ-five-dimensional visual analog scale (quality of life)
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based on EQ-VAS. The patient groups who are in no problem category 
are found to have better QOL. The safety and QOL statistical differences 
constitute less likely among insulin and insulin analogs. The use of 
insulin analogs will continue to advance our efforts at improving 
diabetes care and treated related adverse outcomes can be reduced.
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Table 4: Comorbidity of insulin analogs in study population
S.No. Comorbidity Number of patients in insulin 
analogs n=50 (%)
1. Hypertension 10 (20)
2. Cardio vascular patients 7 (14)
3. Renal disease 2 (4)
4. Anemia 1 (2)
5. Thyroid disorder 10 (20)
6. Gastrointestinal disease 5 (10)
7. Joint disorders 2 (4)
8. Respiratory disorders 3 (6)
9. No comorbidity 10 (20)
Table 5: Comparison of quality of life between insulin and 
insulin analogs
S.No. Types EQ-5D VAS
1. Insulin 75.9
2. Insulin analogs 93.75
5D: Five-dimensional, VAS: Visual analog scale
Table 3: Comorbidity of insulin in study population
S.No. Comorbidity Number of patients in insulin 
n=50 (%)
1. Hypertension 15 (30)
2. Cardio vascular patients 7 (14)
3. Renal disease 3 (6)
4. Anemia 2 (4)
5. Thyroid disorder 5 (10)
6. Gastrointestinal disease 4 (8)
7. Diabetic nephropathy 2 (4)
8. Joint disorders 2 (4)
9. Respiratory disorders 5 (10)
10. No comorbidity 5 (10)
CONCLUSION
The safety among insulin analogs and conventional insulin is being 
studied. Insulin analogs group has a low risk of hypoglycemia when 
compared with the conventional insulin. The QOL was determined 
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